rEECur - May 2017 update
rEECur - International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
- The aim of the rEECur trial is to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects.
- 525 patients will be recruited from across Europe from 2015.
The rEECur trial is progressing well, with patients able to take part in the UK, Spain, Italy, Denmark, France, Norway, Belgium, Finland and Hungary. The trial is expected to be to open to patients in Poland, The Netherlands and the Czech Republic later in 2017.
- 138 patients have been recruited so far
Before any results can be released, we have to wait until we have recruited all the 525 patients and followed them for a period of time to see how they get on with treatment. It will take a number of years to reach the target of 525 patients at which point statisticians will be able to analyse all the information. The data is reviewed regularly by independent bodies to check for any safety concerns. Each person who takes part in the trial provides invaluable data and provides an important contribution Ewing sarcoma research.
We are grateful to those patients who have agreed to join this trial, and to their families, and treating clinical teams across Europe
This page will be updated twice a year.